Free tool
FAERS Monitor: Motofen Half-Strength
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017744 or its brand name (Motofen Half-Strength, Atropine Sulfate, Difenoxin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
26
Serious
15
58% of reports
Hospitalization
10
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vomiting4
- diarrhoea3
- drug ineffective3
- nausea3
- pain3
- product dose omission issue3
- bone disorder2
- fall2
- irritable bowel syndrome2
- product availability issue2
- abdominal distension1
- abdominal pain1
- abdominal pain upper1
- arthrodesis1
- asthenia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 5 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2025 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,133 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| arthrodesis | 1 | 796.2 | 116.4 | 198 |
| bone disorder | 2 | 88.8 | 23.5 | 97 |
| irritable bowel syndrome | 2 | 75.5 | 19.9 | 82 |
| product availability issue | 2 | 71.1 | 18.8 | 77 |
| product dose omission issueSignal | 3 | 8.3 | 2.8 | 13 |
| abdominal distension | 1 | 7.7 | 1.1 | 1 |
| vomitingSignal | 4 | 6.9 | 2.8 | 15 |
| fall | 2 | 4.9 | 1.3 | 3 |
| painSignal | 3 | 4.0 | 1.4 | 4 |
| abdominal pain upper | 1 | 3.9 | 0.6 | 0 |
| diarrhoea | 3 | 3.8 | 1.3 | 4 |
| abdominal pain | 1 | 3.5 | 0.5 | 0 |
| nausea | 3 | 3.1 | 1.1 | 2 |
| asthenia | 1 | 2.2 | 0.3 | 0 |
| drug ineffective | 3 | 1.8 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.